Pharma 5 produces pharmaceutical cannabidiol in Morocco
By the AFREEQUE newsroom, based on Lebrief, Maroc Diplomatique and Yabiladi
Moroccan laboratory Pharma 5 has announced two national firsts in therapeutic cannabis: the production of a cannabidiol-based pharmaceutical active ingredient and the development of a medicine for certain severe forms of epilepsy. Presented as the first 100% Moroccan CBD-based medicine, “Cannabidiol Pharma 5” has been available since 9 November, according to Lebrief.
The project required five years of research and more than 200 million dirhams in investment. The cannabidiol produced is more than 98% pure and meets European Pharmacopoeia requirements, according to Pharma 5.
The medicine is intended for certain severe forms of epilepsy resistant to drug treatments. Pharma 5 says it controls the entire chain, from regulated cannabis cultivation in the Rif to CBD extraction, purification and medicine manufacturing.
The project involves more than 40 hectares of cultivation and benefits 70 farming families in the Rif. More than 100 tonnes of biomass have already been processed to pharmaceutical standards, under Law 13-21 governing the lawful uses of cannabis in Morocco.
